Castle Hook Partners LP Has $24.80 Million Stake in Catalent, Inc. (NYSE:CTLT)

Castle Hook Partners LP trimmed its position in shares of Catalent, Inc. (NYSE:CTLT) by 50.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 409,419 shares of the company’s stock after selling 422,018 shares during the period. Catalent makes up 0.5% of Castle Hook Partners LP’s portfolio, making the stock its 29th biggest holding. Castle Hook Partners LP owned approximately 0.23% of Catalent worth $24,799,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CTLT. Millennium Management LLC boosted its holdings in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after acquiring an additional 2,299,784 shares during the period. Bank of Montreal Can boosted its holdings in Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after acquiring an additional 1,169,044 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after buying an additional 863,624 shares during the period. ING Groep NV lifted its stake in shares of Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after buying an additional 699,851 shares during the period. Finally, Mizuho Markets Americas LLC bought a new stake in shares of Catalent in the third quarter valued at about $30,285,000.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CTLT shares. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $63.40.

Catalent Stock Up 0.4 %

Shares of CTLT opened at $61.00 on Thursday. The stock has a market cap of $11.07 billion, a price-to-earnings ratio of -26.99, a P/E/G ratio of 2.44 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The company has a 50-day moving average price of $59.86 and a two-hundred day moving average price of $58.41.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) EPS. Equities analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock worth $305,931 over the last quarter. Company insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.